医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharmatech to Teach Quality by Design and the new Process Validation Guidance at the 2013 ISPE Australasian Conference

2013年08月27日 PM10:25
このエントリーをはてなブックマークに追加


 

HAYWARD, Calif.

Pharmatech Associates, a regulatory compliance consultancy serving companies in the pharmaceutical, biotech and medical device industries, will lead training sessions on Quality by Design (QbD) and the new Process Validation (PV) requirements at the 2013 ISPE Australasian Conference taking place September 9-11 in Canberra, Australia.

Pharmatech executives Bikash Chatterjee, President and CTO, and Wai Wong, Vice President and General Manager of Worldwide Operations, will address the new quality paradigm that comprises QbD and PV in a case study workshop demonstrating the benefits of these regulatory concepts and an approach for their practical application.

The ISPE Australasian Conference features presentations by leading global industry experts and local practitioners in a program titled “Where Global Knowledge Meets Local Experience” to give professionals and local TGA regulatory authorities a better understanding of the industry’s current technical and regulatory challenges and an opportunity to engage in open dialogue.

ISPE is the world’s largest not-for-profit society serving pharmaceutical and medical device, engineering, science and manufacturing professionals.

About Pharmatech Associates

Pharmatech Associates (founded in 1995) consults to the pharmaceutical, biotech, medical device manufacturing and other regulated life sciences industries. Headquartered in the San Francisco Bay Area, Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in North America, Asia and Europe.

CONTACT

SIPR for Pharmatech
Judy Curtis, +1 650-274-1509
judy@sipr.com

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)